This $225,306 Project Grant award from the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) supports a collaborative research project between researchers at the University of Southern California (USC) and a German partner to investigate the long-term impact of early-life growth signals on adult hematopoietic (blood) stem cell function and selection. The key products and services to be delivered under this 3-year award include: 1) using stem cell transplantation and...
This $792,498 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at Indiana University Indianapolis to investigate the role of oxygen levels in regulating the function and regenerative capacity of hematopoietic stem cells (HSCs). The research aims to elucidate the signaling and metabolic pathways by which hypoxic conditions in the bone marrow promote HSC self-renewal and prevent...
This Project Grant award for $249,000.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) aims to define the molecular basis controlling hematopoietic stem cell (HSC) symmetric and asymmetric divisions. The research, led by Dr. Hanzhi Luo at the Institute For Cancer Research, a non-profit subsidiary of Temple University, seeks to leverage novel systems and high-throughput...
This $295,438 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to expand the availability of suitable donors for hematopoietic stem cell transplantation (HSCT) and reduce post-transplant complications. The primary objectives are to: Determine if supplementation of the pro-hematopoietic factor Netrin-1 (NTN1) can improve the ex vivo expansion and in vivo engraftment of human...
This Project Grant award of $814,209 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to develop in vivo hematopoietic stem cell (HSC) gene therapy using CD90-targeted nanoparticles. The goal is to overcome limitations of current ex vivo HSC gene therapy approaches by enabling direct gene editing of HSCs within the patient's bone marrow. The key objectives are to: 1) optimize nanoparticle formulations...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to define the physiology of blood cell production in the bone marrow tissue during homeostasis, inflammation, and regeneration. The $1,123,357 award, with a project period from January 1, 2025 to December 31, 2031, will enable researchers at the Childrens Hospital Medical Center in Cincinnati, Ohio to: 1) dissect the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), aims to evaluate the use of accessory cells to improve homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will fund research to determine if co-infusing the CD34+ cells with the CD34-negative fraction, normally discarded after CD34+ cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 3-year, $497,806.97 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Trustees of Indiana University, doing business as Indiana University Indianapolis. The award supports research to elucidate molecular programs that can be targeted to enhance the function of hematopoietic stem cells (HSCs) from umbilical cord blood, with the goal of improving hematopoietic cell transplantation (HCT) outcomes for...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $493,810 five-year Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Wisconsin-Madison. The grant funds research to understand the cellular interactions between hematopoietic stem and progenitor cells (HSPCs) and the perivascular niche, with the goal of improving HSPC-based therapies for blood diseases and cancers. The researchers will use zebrafish and mouse models to investigate...
The U.S. National Institutes of Health (NIH) awarded a $1,630,964 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the University of Southern California (USC) to study the spatial dynamics of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. The central hypothesis is that HSPC migration through distinct bone marrow micro-environments exposes them to signals that promote expansion and differentiation during blood and immune cell regeneration. The...
CHARACTERIZATION OF MULTILINEAGE DEFINITIVE HEMATOPOIETIC PROGENITORS FROM HUMAN PLURIPOTENT STEM CELLS - PROJECT SUMMARY / ABSTRACT HEMATOPOIETIC STEM CELLS (HSCS) ARE STEM CELLS THAT REPLENISH THE ENTIRE SUITE OF BLOOD CELLS NEEDED THROUGHOUT ADULT LIFE, AND ARE AN IMPORTANT SOURCE FOR CELL REPLACEMENT THERAPIES AND DISEASE MODELING STUDIES. THE OVERALL GOAL OF OUR RESEARCH IS TO UNDERSTAND HOW TO DERIVE THESE IMPORTANT CELLS, IN A PETRI DISH, FROM HUMAN PLURIPOTENT STEM CELLS (HPSCS). WHILE THE SIGNAL REQUIREMENTS FOR THIS REMAIN UNCLEAR, WE HAVE RECENTLY UNCOVERED A NOVEL DIFFERENTIATION APPROACH, YIELDING CD34+ PROGENITORS THAT HARBOR BOTH TRANSCRIPTIONAL AND FUNCTIONAL PROPERTIES THAT ARE SIMILAR TO NASCENT HSCS. THIS METHODOLOGY EMPLOYS STAGE-SPECIFIC RETINOIC ACID (RA) SIGNALING, AND YIELDS A POPULATION OF CELLS CAPABLE OF HOMING TO RECIPIENT BONE MARROW, AND GIVE RISE TO DIFFERENTIATED PROGENY. WE HYPOTHESIZE THAT THIS POPULATION IS UNIQUE, AND A PRECURSOR TO THE HSC THAT REQUIRES ADDITIONAL SIGNALS DURING ITS SPECIFICATION, TO CONFER SELF-RENEWAL CAPACITY. WE WILL TEST THIS HYPOTHESIS ACROSS 2 SPECIFIC AIMS. IN AIM 1, WE WILL CHARACTERIZE THE TRANSCRIPTIONAL AND SIGNAL DEPENDENCIES FOR THE DEVELOPMENT OF THESE CELLS, AND UNDERSTAND THE ROLE OF DIFFERENTIAL SPLICING IN A CRITICAL TRANSCRIPTION FACTOR. IN AIM 2, WE WILL DEFINE THE TRANSLATIONAL POTENTIAL OF THE LYMPHOID CELLS THAT CAN BE OBTAINED FROM HPSCS, VIA RA-DEPENDENT AND RA-INDEPENDENT MECHANISMS. THE OBJECTIVE OF THESE STUDIES IS TO UNDERSTAND THE DEVELOPMENT AND REGULATION OF HSCS FROM HPSCS, AND WHETHER HSC-INDEPENDENT LYMPHOID CELLS MAY BE A VIABLE ALTERNATIVE SOURCE FOR ADOPTIVE IMMUNOTHERAPEUTICS. THIS IS OF FUNDAMENTAL IMPORTANCE TO BOTH BASIC AND TRANSLATIONAL BIOLOGY, AND THE INSIGHTS GENERATED FROM THESE STUDIES WILL HAVE CLINICAL IMPLICATIONS. OUR UNIQUE CELLULAR AND MOLECULAR TOOLS, COMBINED WITH OUR EXPERTISE IN HEMATOPOIESIS, STEM CELL BIOLOGY AND BIOINFORMATICS PUTS US IN AN IDEAL POSITION TO MAKE A SIGNIFICANT IMPACT IN THIS FIELD.